This week, multiple breakthroughs in the pharmaceutical and life sciences sectors have drawn attention: Kelun Pharmaceutical enters the 700 million anticoagulant track, Zhengya Dental is sprinting
In 2026, investment and financing in medical hard technology will remain hot, with cutting-edge tracks such as AI new drug R&D, brain-computer interfaces, nucleic acid drugs,
– Introduction – Biomedicine is undergoing a round of industrial transformation driven by underlying technologies. Cell therapy, gene therapy, core components of medical devices, and blood
· Xiongan New Area Approved to Build National-level Intellectual Property Protection Center · Ningxia Establishes Overseas Intellectual Property Dispute Response Guidance Expert Database · Anhui Province
Recently, a “Orange Hotel” in Pingdingshan, Henan, which has been operating for nearly ten years, was sued by “Orange Hotel Management (China) Co., Ltd.” for trademark
On June 22, the National Medical Products Administration approved five innovative drugs at once. On this day, Chinese innovative drugs delivered a historic report card—out of
This week, several studies have made key breakthroughs in tumor immunology, regenerative medicine, and drug resistance mechanisms: a team from Peking Union Medical College successfully reversed
This week, financing in biomedicine and hard technology sectors was active: Youyi Bio completed Series A financing, accelerating domestic substitution of serum-free culture media; Westlake Biotech
In May 2026, the global pharmaceutical industry witnessed a historic moment for China’s innovative drugs. In just 17 days, Hengrui, Innovent, and Hisco successively partnered with
On June 10 and 11 local time in the United States, DJI filed a lawsuit in the U.S. District Court for the Eastern District of Texas,
A Leading Chinese Intellectual Property Legal Service Provider